Sharemaestro Newsreel

Raymond James raises Praxis Precision Medicines price target on pipeline outlook

Raymond James has increased its price target for Praxis Precision Medicines Inc. (NASDAQ:PRAX) shares from $765 to $945, maintaining a Strong Buy rating. This upgrade is driven by an increased probability of success for the company's EMERALD trial and higher peak sales forecasts for …

H.C. Wainwright reiterates Alumis stock rating at neutral, $25 target

H.C. Wainwright has reiterated a Neutral rating and $25.00 price target for Alumis Inc (NASDAQ:ALMS), emphasizing upcoming clinical trial results for Sjögren’s disease and systemic lupus erythematosus as critical for the stock's future, potentially opening a second therapeutic path beyond psoriasis. The firm highlights …

H.C. Wainwright reiterates Kodiak Sciences stock rating at buy

H.C. Wainwright has reiterated a buy rating and a $58.00 price target for Kodiak Sciences Inc. (NASDAQ:KOD), highlighting the stock's significant surge over the past year. The firm anticipates key topline data from two Phase 3 trials in September and December 2026, which are …

Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies

Fulcrum Therapeutics and Slate Medicines have announced a definitive merger agreement to combine in an all-stock transaction. The combined entity, to be named Slate Medicines, Inc., will focus on advancing Slate's pipeline of next-generation migraine therapeutics, including SLTE-1009, a clinical-stage subcutaneous anti-PACAP/VIP monoclonal antibody. …

H.C. Wainwright Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $20

H.C. Wainwright has reiterated its Buy rating for Altimmune (ALT.US), maintaining a target price of $20. This indicates the firm's continued confidence in the company's stock performance.

Weekly Recap: Guidance withdrawn over CINVANTI patent and HRTX Q2 revenue $37.7M

Heron Therapeutics Inc (HRTX) has withdrawn its 2026 sales and Adjusted EBITDA guidance due to uncertainty surrounding the CINVANTI patent and an ongoing strategic review. The company reported Q2 revenue of $37.7M, including $11.1M from ZYNRELEF and $4.2M from APONVIE, with a cash balance …

Weekly Recap: Cash runway to Phase 2 readouts and Q2 loss, stock outlook

Palisade Bio, Inc. (PALI) announced that its existing cash reserves are sufficient to fund operations through key Phase 2 readouts expected in 2027–2028. The company is advancing its ASCENTRA-UC Phase 2 program and plans to initiate ASCENTRA-CD in late 2026 to early 2027. For …

Satellos TRAILHEAD Data Suggests Muscle Regeneration as Company Cash Reaches US$61.8M

Satellos Bioscience Inc. released positive six-month TRAILHEAD data showing reduced muscle fat and increased effort in adult Duchenne Muscular Dystrophy (DMD) participants, suggesting improved muscle composition. The company also announced a strong financial position with US$61.8 million in cash, expected to fund operations through …

Jasper Therapeutics beats earnings expectations but stock falls 4%

Jasper Therapeutics Inc. reported better-than-expected second-quarter fiscal 2026 results, with an adjusted loss per share of $0.10 against an estimated loss of $0.28. Despite this beat, the company's stock fell 4.24% in pre-market trading. The company also highlighted its recent acquisition of Kira Pharmaceuticals …

NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter

NRx Pharmaceuticals reported its second-quarter 2026 financial results, highlighting significant progress in advancing its preservative-free ketamine ANDA towards FDA approval and commercialization. The company secured $22.3 million in gross proceeds from a public offering, ensuring over a year of operations, and expanded its clinical …

EyePoint’s DURAVYU misses primary endpoint in wet AMD trial

EyePoint, Inc. announced that its Phase 3 LUGANO trial for DURAVYU in wet AMD treatment failed to meet its primary endpoint, largely due to an asymmetric cohort of patients experiencing vision loss unrelated to wet AMD. Despite this, an ad hoc analysis showed non-inferiority …

69,441 Shares in Edgewise Therapeutics, Inc. $EWTX Bought by Persistent Asset Partners Ltd

Persistent Asset Partners Ltd recently acquired 69,441 shares of Edgewise Therapeutics (EWTX) for approximately $2.82 million, making it their 23rd largest holding. Despite some insider selling to cover tax obligations, analysts maintain a "Moderate Buy" rating with an average price target of $49.08. Edgewise …

SCS Capital Management LLC Purchases New Shares in Bicara Therapeutics Inc. $BCAX

Veradermics, Inc SEC Filing (Aug 17, 2026)

Veradermics, Inc. (NYSE: MANE) had an EFFECT filing accepted by the SEC EDGAR on August 17, 2026, with an effectiveness date of August 14, 2026, at 4:00 P.M. The filing was Form S-1. The company's recent news includes financial results, clinical progress updates, and …

CRIS Reiterated by HC Wainwright & Co. -- Price Target Maintained at $43

HC Wainwright & Co. has reaffirmed its 'Buy' rating for Curis (CRIS), maintaining a price target of $43.00, despite the company's current unprofitability and moderate GF Score™ of 57/100. Although Curis is considered significantly undervalued by GuruFocus's GF Value™ at $20.18 compared to its …

Traws Pharma beats Q2 loss estimates, shares jump 4%

EVGN Q2'26 Earnings: EPS estimate is (0.27) USD

Evogene Ltd. (EVGN) is expected to announce its Q2'26 earnings on August 18th. Analysts anticipate a revenue of 325.00 thousand USD and an EPS of (0.27) USD for the quarter. The article provides a table comparing reported and estimated revenue and EPS for several …

Quince Therapeutics plans special meeting to vote on share issuance and potential change of control

Quince Therapeutics (NASDAQ:QNCX) announced a special meeting to vote on issuing common stock related to converting Series C Preferred Stock and exercising warrants/options. These actions could lead to a dilution of over 20% of outstanding shares and potentially a change of control. The company …

Quince Therapeutics to seek shareholder OK for Series C conversion, adding ~11M shares and reclassifying $6.3M warrants

Quince Therapeutics plans to ask shareholders to approve the conversion of Series C preferred stock and other equity actions, potentially adding about 11 million common shares. This move would reclassify a $6.3 million warrant liability to equity and increase stockholders' equity to $114.8 million. …

AIGH Capital Management LLC Purchases New Stake in Vanda Pharmaceuticals Inc. $VNDA

AIGH Capital Management LLC has acquired a new stake of over 2 million shares in Vanda Pharmaceuticals Inc., valued at approximately $12.5 million, making it their 21st largest position. Analyst sentiment for Vanda Pharmaceuticals is mixed but leans positive, with a "Moderate Buy" consensus …

Monaco Asset Management SAM Invests $1.35 Million in Vanda Pharmaceuticals Inc. $VNDA

Monaco Asset Management SAM has acquired a new stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), purchasing 221,286 shares valued at approximately $1.35 million. This investment makes Vanda Pharmaceuticals 0.1% of Monaco Asset Management SAM's portfolio and represents about 0.37% ownership of the company. The biopharmaceutical …

Persistent Asset Partners Ltd Makes New $1.32 Million Investment in Relay Therapeutics, Inc. $RLAY

Persistent Asset Partners Ltd invested $1.32 million in Relay Therapeutics, acquiring 70,693 shares during Q2. This comes as Relay Therapeutics reported a quarterly loss and revenue miss, while company insiders sold approximately $7.23 million in stock over the past 90 days. Despite mixed analyst …

GSA Capital Partners LLP Purchases New Holdings in Sarepta Therapeutics, Inc. $SRPT

GSA Capital Partners LLP has acquired a new stake in Sarepta Therapeutics (NASDAQ:SRPT), purchasing 103,618 shares valued at approximately $1.86 million, representing 0.10% of the company. Other institutional investors have also adjusted their holdings in SRPT, with institutional ownership collectively standing at 86.68%. Despite …

Broker Revenue Forecasts For Sutro Biopharma, Inc. (NASDAQ:STRO) Are Surging Higher

Sutro Biopharma, Inc. (NASDAQ:STRO) has received significant upgrades to its 2026 revenue and loss forecasts from analysts, with expected revenues increasing to US$51m and losses shrinking to US$8.34 per share. Despite these positive adjustments, the analysts' price target of US$47.23 remains unchanged. The company's …

Raymond James raises Rapport Therapeutics price target on bipolar catalyst potential

Raymond James has increased its price target for Rapport Therapeutics (NASDAQ: RAPP) to $75 from $68, maintaining a Strong Buy rating. This adjustment is based on the anticipated bipolar mania readout for RAP-219, which is considered a significant catalyst. The firm believes a successful …

OneDigital Investment Advisors LLC Makes New Investment in Axsome Therapeutics, Inc. $AXSM

OneDigital Investment Advisors LLC has invested in Axsome Therapeutics, purchasing 7,787 shares valued at approximately $1.9 million during the second quarter. Despite Axsome Therapeutics missing its Q2 earnings and revenue estimates and recent insider selling, analysts maintain a "Moderate Buy" rating with an average …

Legend Biotech Corporation (LEGN): Investor Outlook on a Biotech Powerhouse with 141.76% Potential Upside

Legend Biotech Corporation (LEGN) is highlighted as a significant player in the biotechnology sector, focusing on innovative cell therapies, especially for multiple myeloma. The company shows strong revenue growth despite current net losses, with analysts predicting a 141.76% potential upside. Strategic partnerships and a …

SEER Q2 2026 Earnings: Wider-than-Expected Loss Reflects Continued Proteomics Platform Investment - ROIC Trend Report

AIGH Capital Management LLC Purchases Shares of 1,504,741 PolyPid Ltd. $PYPD

AIGH Capital Management LLC recently acquired 1,504,741 shares of PolyPid Ltd. (NASDAQ:PYPD) for approximately $7.6 million, representing a 7.89% stake and making it their 24th largest holding. PolyPid reported better-than-expected quarterly earnings, with analysts predicting a full-year loss of $1.67 per share. Despite the …

2,792 Shares in Vertex Pharmaceuticals Incorporated $VRTX Purchased by Simplicity Wealth LLC

Simplicity Wealth LLC recently acquired 2,792 shares of Vertex Pharmaceuticals (NASDAQ:VRTX) valued at approximately $1.39 million during the second quarter. Vertex reported quarterly revenue of $3.33 billion, exceeding estimates, though its EPS of $4.73 narrowly missed consensus. The company holds a "Moderate Buy" rating …

Plato Investment Management Ltd Purchases Shares of 6,083 Vertex Pharmaceuticals Incorporated $VRTX

Plato Investment Management Ltd recently acquired 6,083 shares of Vertex Pharmaceuticals (NASDAQ:VRTX) valued at approximately $3 million during the second quarter. Other institutional investors have also increased their holdings, leading to institutions collectively owning 90.96% of the company's stock. Despite some insider selling, analysts …

Trivium Point Advisory LLC Takes Position in Vertex Pharmaceuticals Incorporated $VRTX

Trivium Point Advisory LLC has acquired a new stake in Vertex Pharmaceuticals (NASDAQ:VRTX), purchasing 2,199 shares valued at approximately $1.092 million during the second quarter. Other institutional investors have also recently adjusted their holdings in the pharmaceutical company, which reported quarterly earnings that narrowly …

Incyte stock holds at the $120 mark as strong quarterly earnings support valuation

Incyte stock is holding steady around the $120 mark, supported by strong quarterly earnings that significantly beat analyst expectations and double-digit revenue growth. Despite the positive financial performance, the stock carries a "Hold" consensus rating and is trading close to its average target price, …

Slate, Fulcrum to combine in reverse merger

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Headache drug specialist Slate Medicines said Monday it will combine with struggling biotechnology firm Fulcrum Therapeutics, two months after the latter announced …

Axsome Therapeutics, Inc. (AXSM) Stock Analysis: Significant 33.58% Upside Potential with Strong Buy Ratings

Axsome Therapeutics (AXSM) is a biotechnology company focused on CNS disorders with a strong market capitalization of $11.19 billion. Analysts project a 33.58% upside potential with an average target price of $285.42 and a consensus of 20 buy ratings, driven by impressive revenue growth …

Ocular Therapeutix stock rises as rival’s wet AMD trial stumbles

Ocular Therapeutix Inc (NASDAQ:OCUL) shares rose after its competitor EyePoint Pharmaceuticals (NASDAQ:EYPT) announced that its DURAVYU treatment failed to meet the primary endpoint in a Phase 3 wet AMD trial. EyePoint's trial showed that DURAVYU did not achieve the primary endpoint of visual acuity …